How antimalarial drug resistance affects post-treatment prophylaxis by White, Nicholas J
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Malaria Journal
Open Access Review
How antimalarial drug resistance affects post-treatment 
prophylaxis
Nicholas J White1,2
Address: 1Mahidol-Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Rd., Bangkok 10400, Thailand and 
2Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, OX3 7LJ, UK
Email: Nicholas J White - nickw@tropmedres.ac
Abstract
Slowly eliminated antimalarial drugs suppress malaria reinfections for a period of time determined
by the dose, the pharmacokinetic properties of the drug, and the susceptibility of the infecting
parasites. This effect is called post-treatment prophylaxis (PTP). The clinical benefits of preventing
recrudescence (reflecting treatment efficacy) compared with preventing reinfection (reflecting
PTP) need further assessment. Antimalarial drug resistance shortens PTP. While blood
concentrations are in the terminal elimination phase, the degree of shortening may be estimated
from measurements of in-vitro susceptibility and the terminal elimination half-life. More
information is needed on PTP following intermittent preventive treatments, and on the relationship
between the duration of PTP and immunity, so that policy recommendations can have a firmer
evidence base.
Background
In areas of intense malaria transmission reinfection fol-
lowing antimalarial treatment is inevitable. Antimalarial
drug treatments with slowly eliminated drugs provide a
variable period, after they have cleared the initial infec-
tion, during which subsequent reinfection is suppressed
by residual levels of the antimalarial drug. This effect is
called post-treatment prophylaxis or PTP [1,2]. PTP can
range in duration from months, with very slowly elimi-
nated compounds such as piperaquine and chloroquine,
to none at all with rapidly eliminated drugs such as the
artemisinin derivatives. PTP should provide additional
benefit, above that conferred by effective cure of a symp-
tomatic infection, by allowing a longer disease-free inter-
val for clinical and haematological recovery. The benefits
of preventing reinfection depend on the transmission
intensity and thus the frequency of infection. It has been
argued that preventing reinfection is as important as pre-
venting recrudescence, although this remains to be
proved, both at an individual and population level. The
two are obviously linked as both are measures of antima-
larial efficacy. This individual benefit of longer PTP is bal-
anced against a potential societal harm; the increased
propensity of slowly eliminated antimalarials to select for
resistance [3-5]. PTP is an important component of inter-
mittent preventive treatment, (also sometimes referred to
as intermittent presumptive treatment) in pregnancy
(IPTp) and is probably the most important effect of inter-
mittent preventive treatment in infancy (IPTi), and in
other high risk sub-groups [1,6,7]. The dose and the phar-
macokinetic properties of the drug affect the duration of
PTP. For the prevalent malaria parasites, antimalarial drug
resistance reduces the duration of PTP.
In practice, PTP is measured as the time from drug admin-
istration (either treatment of the first, usually sympto-
matic, infection or administration of IPT to an
asymptomatic person) until the next infection is detecta-
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ble on a blood smear. In areas of very intense malaria
transmission (e.g one infected bite per person per day),
this interval can be assessed in an individual, but at lower
levels of transmission, where infections are acquired at a
low frequency, there is a large stochastic element to the
acquisition of infections, and so populations must be
studied. Prevention of malaria in pregnancy has an addi-
tional component in that the pharmacokinetic properties
of many drugs are altered in late pregnancy. Furthermore
the Plasmodium falciparum parasites which establish in the
placenta bind specifically to chondroitin sulphate A, and
as these infections are considered to be a minority of nat-
ural infections, they may take longer to become estab-
lished than systemic infections. Although IPTp has been
widely introduced with sulphadoxine-pyrimethamine
(SP), and there is increasing support for IPTi, there have
not been sufficient studies to characterize the critical rela-
tionship between the duration of PTP for the candidate
drugs and resistance to them to guide policy. Here, the
relationship between the level of antimalarial drug resist-
ance and the duration of PTP is reviewed from a pharma-
cological perspective, and suggestions provided for future
investigations.
Pharmacokinetic determinants
Malaria parasites infect red blood cells. To kill, or to
inhibit the development of the intraerythrocytic parasite,
the antimalarial drug must enter the infected red cell and
attain a sufficient intraparasitic concentration. The biolog-
ically relevant component of antimalarial drug content in
blood is the free plasma concentration (Cf), as this is
thought to reflect best the concentrations to which the
malarial parasite is exposed. Concentration gradients exist
within the parasite, and there may be considerable accu-
mulation within the food vacuole, but all depend on the
concentration of antimalarial in plasma water. Cf is the
product of the total plasma concentration (C) and the
proportion of plasma drug in plasma water (i.e. unbound
to plasma proteins) – the free fraction (f).
The concentration of drug in blood at any time is deter-
mined by several independent variables; the rate of
absorption, the fraction of drug absorbed (the bioavaila-
bility), the apparent volume(s) of distribution, and the
rates of distribution and clearance. Each of these may be
affected by the disease process and the physiological
changes occurring in pregnancy or infancy. All the antima-
larial drugs are eliminated by a first order process, and in
this review it is assumed that PTP still occurs during the
terminal elimination phase of the drug. The calculations
focus on this phase.
i.e. at any time (t) in this phase C ft = C f0 e-kt
where C f0 is the intercept back extrapolated to time = 0 for
the terminal phase, and k is the first order terminal elimi-
nation rate constant
k = ln2/t1/2 where t1/2 = the terminal elimination half life.
Although essentially derivative, the terminal elimination
half-life is a familiar concept to most clinicians and malar-
iologists and so will be the main variable used in the fol-
lowing examples.
Pharmacodynamic determinants
The level of resistance determines the antimalarial drug
effect at any given drug concentration. Unfortunately it is
not possible to extrapolate directly from in-vitro to in-vivo
measurements of drug susceptibility, although clearly
there is a relationship between the two.
If the minimum inhibitory concentration (MIC) is the
lowest concentration inhibiting multiplication
i.e. the concentration at which parasite multiplication rate
(PMR) = 1
then MIC in vivo = f MIC in vitro
Assuming this to be a linear function then
0.5 × MIC in vivo = 0.5 × f MIC in vitro
In the terminal elimination phase the time taken for drug
concentrations to fall by half is then, by definition, one
half-life.
Put another way, provided that the MIC values remain
below the concentrations which occur at the end of the
distribution phase (i.e. the beginning of the terminal
elimination phase), then resistance which results in a
doubling of the MIC will shorten the duration of PTP by
one half-life [1]. So during the terminal elimination
phase, if the MIC increases N, fold the corresponding
reduction in PTP duration measured in terms of half-lives
is log2 N (log2 is the logarithm to the base 2) (Figure 1).
Immunity also inhibits parasite development and multi-
plication and thereby augments the effects of antimalarial
drugs. This explains the greater efficacy of failing antima-
larial drugs in areas of moderate to high malaria transmis-
sion in older children and adults. It also explains why IPTp
with SP appears to provide benefit even in the face of sig-
nificant resistance. In effect immunity moves the dose-
response relationship to the left (i.e. the opposite direc-
tion to resistance). The calculations that follow assume
either no immunity or a constant effect of immunity. If a
drug has a single terminal elimination phase then there isMalaria Journal 2008, 7:9 http://www.malariajournal.com/content/7/1/9
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a predictable limit to the possible effect of resistance on
PTP. If the maximum duration of PTP with fully sensitive
parasites is "P" half-lives then it is obviously not possible
to shorten PTP by more then P half-lives. So, with the pro-
visos above, there is no PTP once MICs have risen to the
level where
N = log2P × P (1)
For example if the maximum PTP is 16 half-lives (in fully
sensitive parasites) then there is no PTP at all if the MICs
rise more than 64 fold (64 = log216 × 16).
Unfortunately, there are not very accurate estimates of in-
vivo MIC, nor of PTP durations against sensitive parasites,
although Watkins et al [8] have estimated a figure of
approximately 60 days for fully sensitive P. falciparum fol-
lowing SP administration, and PTP is certainly more than
a month for both chloroquine and mefloquine against
fully sensitive P. falciparum and Plasmodium vivax.
The relationship between antimalarial drug concentration
and inhibition of parasite growth is generally sigmoid (1)
but the relationship between inhibition of growth and
inhibition of parasite multiplication has not been well
characterized. Nor is it clear how immunity affects this
relationship. Resistance results in a shift to the right of the
antimalarial concentration-growth inhibition (dose-
response) curve. If the slope does not change then the
respective positions on the curve also do not change
(Figure 2).
Assuming a parallel shift in the dose response (concentra-
tion-effect) relationships and linear relationship between
inhibition of growth and inhibition of multiplication,
then, with these two important provisos, the change in
IC50 with resistance is exactly equivalent to the change in
MIC.
i.e. Δ IC50 = Δ MIC
For example, if there was an eight-fold increase in IC50
there would be a corresponding eight fold increase in
MIC, and so, from equation (1), the duration of PTP
would be reduced by log2 8 – or three fold (Figure 1).
Untramelled parasite multiplication can theoretically
achieve a multiplication rate equal to the mean number of
viable merozoites per schizont at schizont rupture. In
non-immune patients and volunteers multiplication rates
averaging approximately 8–10/cycle have been observed
(although rates over 20 have been documented in some
individuals) [9,10]. The MIC is defined as the antimalarial
drug concentration giving a net growth rate of 1, so the
MIC is certainly not at the "bottom" of the concentration-
effect curve. Inhibition of growth still occurs at sub-MIC
Worsening resistance; the antimalarial concentration-effect  relationship moves to the right Figure 2
Worsening resistance; the antimalarial concentration-effect 
relationship moves to the right. In this example the shift is 
parallel. IC50 is the concentration giving 50% of maximum 
effect, and Emax is the maximum effect possible. Usually in-
vitro susceptibility is assessed by growth inhibition, inhibition 
of uptake of 3H Hypoxanthine, or inhibition of formation of 
pLDH or PfHRP2.
Emax
log concentration
Effect
IC50
Resistance
In this diagram a slowly eliminated drug given over three days  has a single component (monoexponential) elimination phase  with a half-life of 5.5 days Figure 1
In this diagram a slowly eliminated drug given over three days 
has a single component (monoexponential) elimination phase 
with a half-life of 5.5 days. This corresponds with a one-com-
partment model. The vertical axis has a logarithmic scale. 
The in-vivo MIC is 1.25 μmol/L. Each doubling of MIC short-
ens the PTP by one half-life.
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Blood concentration (μmol/L)
0 1 234
20
10
 5
2
1
MIC
2 x MIC
4 x MIC
8 x MIC
16 x MIC
t1/2
t1/2
t1/2
t1/2Malaria Journal 2008, 7:9 http://www.malariajournal.com/content/7/1/9
Page 4 of 7
(page number not for citation purposes)
concentrations. Thus, when plasma (or blood) concentra-
tions of antimalarial drug have fallen below the MIC, par-
asite growth is possible, but the rate of parasite expansion
is reduced because of residual drug effects. Fully efficient
multiplication is possible only when concentrations have
fallen to the bottom of the concentration-effect curve
(figure 2).
The longer the t1/2 the longer is this period of sub-MIC
residual suppression and the longer the interval from fall-
ing below MIC levels to the appearance of patent parasi-
taemia. If the resistant parasites have a fitness
disadvantage conferring reduced multiplication, then the
interval is further prolonged.
Multiphasic elimination
Several of the antimalarial drugs (such as chloroquine,
desethylamodiaquine, tafenoquine, pyronaridine, meflo-
quine, piperaquine) have complex pharmacokinetic prop-
erties as they bind extensively to tissues and have large
total apparent volumes of distribution and multiphasic
elimination profiles with a long terminal phase. These
elimination profiles can be characterized by a series of
exponential terms. For example, chloroquine has a termi-
nal elimination half-life of one to two months. Piper-
aquine also has a very long terminal elimination half-life.
If the duration of PTP is six weeks then it is obviously not
possible to shorten this by more than one half life. With
increasing resistance the concentrations required for inhi-
bition of parasite growth rise above those seen in the ter-
minal phase. The duration of PTP is determined then by
distribution processes, and chloroquine becomes effec-
tively a "shorter half-life drug". This results in a non-linear
relationship between duration of PTP and the in-vivo MIC
(Figure 3). A drug with a single terminal elimination
phase characterised by a single exponential term is shown
in Figure 1, and a multiphasic elimination profile in
Figure 3.
Population considerations
So far the hypothetical changes that would occur in an
individual confronted with different parasites have been
considered. But in reality a population of individuals, in
whom pharmacokinetic properties often differ considera-
bly, confront populations of malaria parasites with differ-
ent drug susceptibilities. These two distributions are
unrelated. The distribution of antimalarial pharmacoki-
netic variables is often approximately normal or log nor-
mal, whereas susceptibility distributions can be either
continuous (e.g. often for quinolines and related drugs)
or multimodal (antifolates). Following antimalarial treat-
ment in a high transmission setting the most resistant par-
asites will, by definition, tend to establish themselves first
in a subject as blood concentrations decline. This is the
force that underlies selection of resistance in the elimina-
tion phase. It is also why examining parasites causing rein-
fections after treatment or intermittent prophylaxis with a
slowly eliminated drug gives a false impression of the
degree and prevalence of antimalarial drug resistance.
In a high transmission setting the cumulative probability
of detecting parasitaemia following treatment will be
determined by pharmacokinetic-pharmacodynamic (PK-
PD) factors; it is a mirror of the population profile of anti-
malarial activity (a function of the population's elimina-
tion phase kinetics and the distribution and shapes of the
parasite growth inhibition curves). In low transmission
settings, this is more complex as the stochastic element
determining the probability of being bitten by an infected
mosquito is much larger. The average duration of PTP at a
population level may be defined as the duration for which
suppression of a certain proportion of reinfections is sup-
pressed. In a high transmission setting this could be time
to 20% (t20) or 50% (t50) prevalence of reinfection
(Figure 4). In a low transmission setting this is more diffi-
cult to characterise. If there are different resistance geno-
types prevalent then these values should ideally be
defined for each genotype (as in the example and
Figure 5).
Three levels of antimalarial susceptibility for a slowly elimi- nated antimalarial with a multiphasic elimination profile (e.g  chloroquine, piperaquine) are shown reflected by the respec- tive minimum inhibitory concentrations (MIC); sensitive (S),  resistant (R) and highly resistant (HR) Figure 3
Three levels of antimalarial susceptibility for a slowly elimi-
nated antimalarial with a multiphasic elimination profile (e.g 
chloroquine, piperaquine) are shown reflected by the respec-
tive minimum inhibitory concentrations (MIC); sensitive (S), 
resistant (R) and highly resistant (HR). Post treatment proph-
ylaxis for sensitive parasites is six weeks. In this example 
increasing levels of resistance progressively shorten the PTP 
from six to three weeks (a) and then from three to two 
weeks (b).
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Example (Figure 5)
In parts of Tanzania, the EIR was 350 infectious bites per
person per year (1/day). At one point the prevalence of the
PfDHFR Asn108 mutation, conferring an approximate
ten-fold reduction in susceptibility, among parasites was
at one time 5% and the remaining parasites were "wild
type". In the 1950s Pyrimethamine alone (t1/2 3 days) was
widely used as treatment. The average PTP against para-
sites with the Asn108 mutation would be expected to be
reduced by log2 10 × 3 = 10 days compared with that
against sensitive parasites.
With one infection per day and a 5% prevalence of the
PfDHFR Asn108 mutation there would therefore be a
50% probability of acquiring such an infection within a
10 day period. Thus, although the background prevalence
of resistant parasites was 5% the proportion of resistant
parasites causing the first reinfection would have been
expected to be approximately 55%. It is important to note
that finding an increased proportion of "resistant" para-
sites during the terminal elimination phase of a slowly
eliminated drug is expected [11]. It is an indicator of the
selective pressure, but many other factors also influence of
degree of selection.
Immunity
Immunity reduces the probability of an infection becom-
ing patent. Immunity to malaria parasites is complex and
poorly defined, but is generally unrelated to drug resist-
ance. In malaria endemic areas therapeutic responses vary
with age as young children have little or no immunity
compared with older children and adults. Immunity
results in better therapeutic responses for any level of
resistance. Even in areas of low transmission cure rates for
any failing drug (with pharmacokinetics which are not age
dependent) are higher in adults than children. Intermit-
tent preventive treatment with sulphadoxine-pyrimeth-
amine in pregnancy appears still to be beneficial where
14-day failure rates in young children are as high as 40%
[6]. Immunity, therefore, contributes to PTP, but the
Post treatment prophylaxis following a slowly eliminated antimalarial such as chloroquine or piperaquine in a high transmission  setting (left figure) where the EIR is 1000/year and in a low transmission setting where the EIR is 1/year Figure 4
Post treatment prophylaxis following a slowly eliminated antimalarial such as chloroquine or piperaquine in a high transmission 
setting (left figure) where the EIR is 1000/year and in a low transmission setting where the EIR is 1/year. The drug concentra-
tions are shown in red and the vertical bars represent cumulative incidence of reinfection; t20 and t50 are the times to reach a 
20% and 50% cumulative incidence of reinfection.
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The figure refers to the example Figure 5
The figure refers to the example. The drug concentrations 
are shown in red, the cumulative incidence of reinfection 
with resistant parasites is shown in blue, and the cumulative 
incidence of reinfection with sensitive parasites is shown in 
green.
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interaction between immunity and treatment responses
has not been well characterized.
Discussion
Antimalarial drug resistance shortens the period of post-
treatment prophylaxis. This is evident from prospective
therapeutic studies in both falciparum and vivax malaria.
In infections with tropical "strains" of P. vivax, the first
sign of chloroquine resistance is the appearance of parasi-
taemia within 28 days of starting chloroquine treatment
[12]. This represents breakthrough of the first relapse
(which normally becomes patent around three weeks after
starting treatment), and is suppressed in chloroquine-sen-
sitive P.vivax infections [2]. In falciparum malaria, reinfec-
tions occur earlier and earlier as resistance worsens. The
changing pattern is determined by the unrelated distribu-
tions of host pharmacokinetics and parasite susceptibility.
Post-treatment prophylaxis is an important component of
treatment responses [13] and is probably the main com-
ponent of IPT. Unfortunately, there are very few data on
the duration of PTP following IPT. Obtaining this infor-
mation is necessary in order to determine the relationship
between PTP and important clinical end-points such as
anaemia and birthweight, and thus the effects of resist-
ance [14]. This would help considerably to rationalize IPT
policy, as there are currently no guidelines on when to
stop IPT in the face of increasing resistance. Conducting
trials with clinical end-points, or even their surrogates
(e.g. placental parasitaemia) requires very large sample
sizes and, therefore, is both costly and time consuming.
Importantly information on PTP is already available
within prospective drug trials which have adequate dura-
tions of follow up (> 28 days), although it is usually not
examined explicitly. PTP should be assessed in the rele-
vant patient group as it is clearly affected by immunity,
and the pharmacokinetic properties of the drug may well
be altered in the target group. SP is the most widely used
drug for IPT. The "standard" doses used have been extrap-
olated from studies in non-pregnant adults, yet we have
only recently learned that the pharmacokinetic properties
of SP are markedly altered and drug levels consequently
lower in two of the main IPT target groups – pregnant
women and young children aged 2–5 years [15,16].
Unfortunately there are still no data at all on the pharma-
cokinetic properties of SP in infancy.
Assessing PTP requires measurement of drug levels,
although for drugs with terminal elimination half-lives of
less than one week these levels have commonly fallen
below levels of detection when the first reinfection occurs.
In these cases, earlier measurement (e.g. the day 7 level)
helps with interpretation [17]. Ideally studies would have
both an individual pharmacokinetic assessment and a test
of parasite susceptibility – but culturing the low density
parasitaemias at first reinfection is often difficult.
Fortunately molecular markers of resistance are now avail-
able for several of the antimalarial drugs-notably SP, and
these can be assessed in samples from patients with low-
density parasitaemias. Antimalarial drugs are a central
component of malaria control, but they are threatened by
increasing resistance [18]. Fortunately new drugs are
becoming available. By characterizing the pharmacoki-
netic and pharmacodynamic properties of the antimalar-
ial drugs in the appropriate patient groups, their use can
be rationalised and optimised.
Abbreviations
Distribution phase
The phase following drug administration during which
the drug distributes to and exchanges with the tissues.
During this phase blood concentrations may fall faster
than during the elimination phase.
Elimination phase
Following distribution, the period during which the drug
is being eliminated. This may have one or more phases.
The last is the terminal elimination phase, which for all
antimalarial drugs is a first-order process, and therefore
has a half-life (the terminal elimination half-life).
EPI
Expanded programme of immunizations
First order kinetics
A reaction rate in which the rate is proportional to the
concentration. In the case of drug (or malaria parasite)
elimination the rate of reduction in blood concentrations
at any time is proportional to the concentration at that
time. The result is that a fixed fraction of the drug (or par-
asites) is cleared per unit time. When plotted on a semi-
log scale the plot is linear, and if the vertical axis is in nat-
ural logarithms (loge), then the slope gives the first order
rate constant (k).
IPT
Intermittent preventive or presumptive treatment. A treat-
ment dose of antimalarial (most studies have been with
SP) is given at fixed times to treat and prevent malaria.
IPTp
IPT in pregnancy. In HIV negative pregnant women, two
doses are given – one in the second and one in the third
trimester
IPTi
IPT in infants. Treatment doses are usually given with EPI
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IPTc
IPT in children – sometimes called sIPT. Treatment doses
are given to young children in areas with seasonal malaria
during periods of peak transmission.
IPTa
IPT in adults. Treatment doses are given to adults going to
or working in areas with seasonal malaria during periods
of peak transmission.
MIC
Minimum Inhibitory Concentration (MIC) is the lowest
concentration inhibiting parasite multiplication i.e. the
concentration at which parasite multiplication rate per
asexual cycle = 1.
PTP
Post-treatment prophylaxis; the suppression of newly
acquired malaria infections by residual antimalarial drug
concentrations following a treatment dose.
SP
Sulphadoxine-pyrimethamine
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